ERBB2 and breast cancer: Furthermore, antitumor and anti‐metastatic effects of chemotherapy (docetaxel) and anti‐VEGFR2 therapy (mAb DC101) are markedly enhanced by CTCE‐9908 in a mouse mammary tumor virus (MMTV)‐driven Polyoma Middle T Antigen (PyMT) transgenic mouse model of breast cancer with HER2/neu overexpression, suggesting a potential novel strategy of combined therapies against cancer 77.